Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice

Behavioural Brain Research

Volumn 217, Issue 2, 2011, Pages 432-438

  Lazzari, Paolo ^a,b   Sanna, Angela ^a   Mastinu, Andrea ^a,b   Cabasino, Simona ^b   Manca, Ilaria ^a,b   Pani, Luca ^a,b  

^a Neuroscienze PharmaNess Scarl ^*  (Italy)

^b Sezione di Cagliari   (Italy)

Author keywords

DIO mice; Food intake; Hypothalamus; Leptin; Rimonabant

Indexed keywords

AGOUTI RELATED PROTEIN; CANNABINOID 1 RECEPTOR; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; LEPTIN; LEPTIN RECEPTOR; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY METABOLISM; FEEDBACK SYSTEM; FOOD INTAKE; GENE EXPRESSION; HYPOTHALAMUS; INTRAABDOMINAL FAT; LIPID DIET; LONG TERM CARE; MOUSE; NEUROMODULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; DIET; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPOTHALAMUS; LEPTIN; MICE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 78650420359     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.022     Document Type: Article

References (52)

1. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006, 355:763-778.
2. Ahren B., Simonsson E., Scheurink A.J., Mulder H., Myrsen U., Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 1997, 46:97-106.
3. Akbas F., Gasteyger C., Sjodin A., Astrup A., Larsen T.M. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 2009, 10:58-67.
4. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
5. Bouret S.G., Draper S.J., Simerly R.B. Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 2003, 304:108-110.
6. Calignano A., Kátona I., Désarnaud F., Giuffrida A., La Rana G., Mackie K., et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000, 408:96-101.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
8. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:L113-117.
9. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., et al. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003, 27:289-301.
10. Cota D., Tschop M.H., Horvath T.L., Levine A.S. Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. Brain Res Rev 2006, 51:85-107.
11. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007, 23:507-517.
12. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res 2008, 36:135-145.
13. Cota D., Sandoval D.A., Olivieri M., Prodi E., D'Alessio D.A., Woods S.C., et al. Food Intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesità 2009, 17:1641-1645.
14. Després J.P., Golay A., Sjostrom L. Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
15. Després J.P., Ross R., Boka G., Alméras N. Lemieux I; ADAGIO-lipids investigators. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009, 29:416-423.
16. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
17. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
18. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov 2008, 7:438-455.
19. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
20. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
21. Martín-García E., Burokas A., Martín M., Berrendero F., Rubí B., Kiesselbach C., et al. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem 2010, 112:1338-1351.
22. Gary-Bobo M., Elachouri G., Gallas J.F., Janiak P., Marini P., Ravinet-Trillou C., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatology 2007, 46:122-129.
23. Hansen H.H., Hansen G., Tang-Christensen M., Larsen P.J., Axel A.M., Raben A., et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010, 636:88-95.
24. Horton R. The neglected epidemic of chronic disease. Lancet 2005, 366:1514.
25. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., et al. The CB1 receptor antagonist Rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005, 19:1567-1569.
26. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002, 967:379-388.
27. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat Rev Drug Discov 2008, 7:961-962.
28. Jovanovic Z., Tung Y.C., Lam B.Y., O'Rahilly S., Yeo G.S. Identification of the global transcriptomic response of the hypothalamic arcuate nucleus to fasting and leptin. J Neuroendocrinol 2010, 22:915-925.
29. Korner J., Leibel R.L. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003, 349:926-928.
30. Lin S., Thomas T.C., Storlien L.H., Huang X.F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 2000, 24:639-646.
31. Matias I., Bisogno T., Di MarzoV. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes 2006, 30:S7-S12.
32. Matias I., Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007, 18:27-37.
33. Matias I., Vergoni A.V., Petrosino S., Ottani A., Pocai A., Bertolini A., et al. Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 2008, 54:206-212.
34. Maynadier M., Basile I., Gary-Bobo M. Adiponectin normalization: a clue to the anti-metabolic syndrome action of Rimonabant. Drug Discovery Today 2009, 14:192-197.
35. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
36. Pfitzer T., Niederhoffer N., Szabo B. Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. Br J Pharmacol 2004, 142:943-952.
37. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
38. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005, 7:65-72.
39. Ravinet T.C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
40. Ravinet T.C., Delgorge C., Menet C., Arnone M., Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640-648.
41. Rigamonti A.E., Giordani C., Bonomo S.M., Cella S.G., Muller E.E. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 2006, 542:116-120.
42. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
43. Salamone J.D., McLaughlin P.J., Sink K., Makriyannis A., Parker L.A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007, 91:383-388.
44. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. Efficacy and tolerability of Rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
45. Thornton-Jones Z.D., Vickers S.P., Clifton P.G. The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food. Psychopharmacology 2005, 179:452-460.
46. Thornton-Jones Z.D., Kennett G.A., Benwell K.R., Revell D.F., Misra A., Sellwood D.M., et al. The cannabinoid CB1 receptor inverse agonist, Rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006, 84:353-359.
47. Tonstad S. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006, 16:156-162.
48. Verty A.N., McFarlane J.R., McGregor I.S., Mallet P.E. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004, 145:3224-3231.
49. Verty A.N., Allen A.M., Oldfield B.J. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity 2009, 17:254-261.
50. Waxman A. WHO global strategy on diet, physical activity and health. Food Nutr Bull 2004, 25:292-302.
51. Yu Y., Deng C., Huang X.F. Obese reversal by a chronic energy restricted diet leaves an increased Arc NPY/AgRP, but no alteration in POMC/CART, mRNA expression in diet-induced obese mice. Behav Brain Res 2009, 205:50-56.
52. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases?. J Cardiometab Syndr 2008, 3:30-34.